Emergent BioSolutions
EBS
#6744
Rank
S$0.83 B
Marketcap
S$15.60
Share price
3.88%
Change (1 day)
23.08%
Change (1 year)

Emergent BioSolutions (EBS) - Total liabilities

Total liabilities on the balance sheet as of September 2025 : S$1.13 Billion

According to Emergent BioSolutions 's latest financial reports the company's total liabilities are S$1.13 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Emergent BioSolutions - Total liabilities on balance sheet (from 2004 to 2025)

Total liabilities by year

Year Total liabilities Change
2024-12-31S$1.23 B-20.49%
2023-12-31S$1.55 B-34.98%
2022-12-31S$2.38 B31.01%
2021-12-31S$1.81 B-4.21%
2020-12-31S$1.90 B13.76%
2019-12-31S$1.67 B0.33%
2018-12-31S$1.66 B688.22%
2017-12-31S$0.21 B-60.97%
2016-12-31S$0.54 B1.35%
2015-12-31S$0.53 B4.82%
2014-12-31S$0.50 B192.46%
2013-12-31S$0.17 B16.64%
2012-12-31S$0.14 B-11.4%
2011-12-31S$0.16 B3.22%
2010-12-31S$0.16 B15.3%
2009-12-31S$0.14 B8.3%
2008-12-31S$0.13 B-11.21%
2007-12-31S$0.14 B-3.74%
2006-12-31S$0.15 B126.37%
2005-12-31S$67.59 M-10.14%
2004-12-31S$75.21 M
2002-12-31S$32.33 M-69.74%
2001-12-31S$0.10 B

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
Merck
MRK
S$100.48 B 8,737.68%๐Ÿ‡บ๐Ÿ‡ธ USA
SIGA Technologies
SIGA
S$36.39 M-96.80%๐Ÿ‡บ๐Ÿ‡ธ USA
GlaxoSmithKline
GSK
S$79.31 B 6,876.03%๐Ÿ‡ฌ๐Ÿ‡ง UK
Celldex Therapeutics
CLDX
S$64.8 M-94.30%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
S$149.65 B 13,062.78%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
S$42.19 B 3,611.10%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Soligenix
SNGX
S$4.78 M-99.58%๐Ÿ‡บ๐Ÿ‡ธ USA